Patents Represented by Attorney, Agent or Law Firm Charles M. Kinzig
  • Patent number: 7553870
    Abstract: The use of polyunsaturated fatty acids of the ?-3 series such as eicosapentaenoic acid (EPA, C20:5 ?-3), docosahexaenoic acid (DHA, C22:6 ?-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: June 30, 2009
    Assignee: Pro Aparts Investimentos E Consultoria LDA
    Inventor: Hajime Shibuya
  • Patent number: 7439255
    Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: October 21, 2008
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Hongxing Yan, Michael R. Palovich, Dramane I. Laine
  • Patent number: 6835712
    Abstract: Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: December 28, 2004
    Assignees: SmithKline Beecham p.l.c., Cambridge University Technical Services Ltd.
    Inventors: Patrick Camilleri, Philippe Guedat, Anthony John Kirby, Andreas Kremer
  • Patent number: 6830714
    Abstract: A process, and a suitable apparatus, for production of particles of a material in which stream of a dispersion of the material in a solvent and a stream of a compressible fluid antisolvent substance are mixed under conditions such that the substance is in compressible fluid antisolvent state. The mixture then flows along a conduit (17) toward an orifice (18), from which it flows into a downstream region in which the compressible fluid antisolvent substance decompresses and the material is isolated in a particulate state. Preferably the antisolvent substance is a supercritical fluid. The process and apparatus can generate a co-formulation of the material with additives which can be introduced in a suitable aqueous or solvent based carrier vehicle.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: December 14, 2004
    Assignee: SmithKline Beecham plc
    Inventors: Petrus Paulus Cornelis Avontuur, David Roy Merrifield, Andrew Robert Souter, Christopher Edmund Valder, John Peter Warr
  • Patent number: 6825188
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Patent number: 6818655
    Abstract: The present invention relates to quinolines, pharmaceutical compositions containing them and their use as antagonists of urotensin II.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 16, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Steven D. Knight, Gregory L. Warren
  • Patent number: 6815457
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterized in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm−1; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226 cm−1; and/or (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: November 9, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Paul David James Blackler, Robert Gordon Giles, Michael Sasse
  • Patent number: 6806369
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: October 19, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Kelly M. Aubart, Siegfried B. Christensen, IV, Jacques Briand, Maxwell David Cummings
  • Patent number: 6806280
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2, 4-dione, maleic acid salt (the “Polymorph”) characterized in that it provides: (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm−1; and/or (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm−1; and/or (iii) a solid-state 13C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (v) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: October 19, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham (Cork) Limited
    Inventors: Paul David James Blackler, Christine Marie Browne, Timothy G. Coakley, Robert Gordon Giles, Gillian Morrissey
  • Patent number: 6803376
    Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 12, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Peter C. Appelbaum, Kim L. Credito, Todd Davies, Diane B. Hoellman, Linda M. Kelly, Glenn A. Pankuch
  • Patent number: 6803369
    Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 12, 2004
    Assignees: SmithKline Beecham Corporation, SmithKlineBeecham p.l.c.
    Inventors: Symon G. Erskine, Michael Gwynn, Neil David Pearson, Edwina Imogen Wilding
  • Patent number: 6800486
    Abstract: A novel method for the determination of amino acids by HPLC using pre-column derivatization is described. In this procedure, the aminno acids are derivatized with 2-chlorobenzoxazole to yield highly fluroresent N-(2-benzoxazolyl)-amino acids (BOX-AAs) for detection at very high sensitivity. Derivatives can also be detected using conventional UV detection methods. The BOX-AAs can be separated on a C18 reversed phase column for quantitative estimation. This method can be used for the preparation of N-(2-benzoxazolyl)-amino acids in large amounts.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: October 5, 2004
    Assignee: SmithKline Beecham Corporation
    Inventor: Kalyan R Anumula
  • Patent number: 6797730
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: September 28, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Jia-Ning Xiang, Siegfried B. Christensen, IV, Jinhwa Lee
  • Patent number: 6783773
    Abstract: Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 31, 2004
    Assignee: Beecham Pharmaceuticals (Pte) Limited
    Inventors: Kevin H. Storm, Creighton P. Conley, John A. Roush
  • Patent number: 6774127
    Abstract: Novel pyridyl and pyrimidinyl substituted pyrazole and pyrazoline compounds and compositions for use in therapy.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: August 10, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Timothy Gallagher, Irennegbe Kelly Osifo
  • Patent number: 6770462
    Abstract: A method for inserting a cassette into a nucleic acid molecule to produce a modified nucleic acid molecule, e.g., a nucleic acid-cassette fusion, is described. The method involves the use of polymerase chain reaction, thereby permitting precise targeting of the desired site in the molecule, but does not require ligation. Also described is the use of this method for high throughput screening the resulting modified nucleic acid molecules.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: August 3, 2004
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Alison F. Chalker, David J. Holmes, Robert Dwayne Lunsford, James Yigong Ge
  • Patent number: 6770657
    Abstract: The invention relates to novel isoquinolines and their use as anticonvulsant and in the treatment of a variety of disorders.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: August 3, 2004
    Assignee: Smithkline Beecham p.l.c.
    Inventors: John David Harling, Mervyn Thompson
  • Patent number: 6767922
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 27, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Patent number: 6762192
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1 is hydrogen, C1-6 alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3CO—, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO—, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6 where R5 is hydrogen or C1-4 alkyl, and R6 is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: July 13, 2004
    Assignee: SmithKline Beechum p.l.c.
    Inventors: John David Harling, Frank Peter Harrington, Mervyn Thompson
  • Patent number: D493518
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: July 27, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Stephen Mark McAllister, Brian Hewitt